Suppr超能文献

移位贵要静脉动静脉内瘘的长期预后

Long-term outcomes of transposed basilic vein arteriovenous fistulae.

作者信息

Moossavi Shahriar, Tuttle Audrey B, Vachharajani Tushar J, Plonk George, Bettmann Michael A, Majekodunmi Omotayo, Russell Gregory B, Regan John D, Freedman Barry I

机构信息

Department of Internal Medicine/Nephrology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, U.S.A.

出版信息

Hemodial Int. 2008 Jan;12(1):80-4. doi: 10.1111/j.1542-4758.2008.00245.x.

Abstract

The need for reliable, long-term hemodialysis vascular access remains critical. To determine the long-term outcomes of transposed basilic vein arteriovenous fistulae (BVT) and their comparability with other vascular accesses, we determined retrospectively the primary and secondary patency rates in 58 BVT and in a total of 58 arteriovenous fistulae (AVF) and arteriovenous grafts (AVG) at a single center. Fifty-eight BVT were placed in 57 individuals, 69% after prior vascular access failure. Ten BVT failed before initial use and 2 patients expired with functioning accesses before dialysis initiation. In all 58 BVT, 46.8+/-10.8% functioned at 3 years, with median survival 30.8 months. Limiting analyses to the 46 BVT that were ultimately accessed, 3-year primary and secondary patency rates were 38.3+/-7.7% and 56.5+/-12.6%, respectively. Lower ejection fraction (p=0.054) and greater numbers of prior permanent dialysis catheters (p=0.005) were present in those with failed BVT. Compared with AVF, BVT had similar 3-year primary and secondary patency rates. The secondary patency rate was significantly better for BVT vs. AVG over the observation period; at 3 years, the rates were 56.5+/-12.6% vs. 9.1+/-6.0% (p=0.002), respectively. Basilic vein arteriovenous fistulae are valuable hemodialysis accesses. Although nearly 20% of newly placed BVT will not function before first use, those that are functional have median survivals exceeding 6 years, and 38% will not require intervention within 3 years of initial use.

摘要

对可靠的长期血液透析血管通路的需求仍然至关重要。为了确定转位贵要静脉动静脉内瘘(BVT)的长期结果及其与其他血管通路的可比性,我们在单一中心回顾性地确定了58例BVT以及总共58例动静脉内瘘(AVF)和动静脉移植物(AVG)的初级和次级通畅率。58例BVT植入了57例个体,69%是在先前血管通路失败后进行的。10例BVT在初次使用前失败,2例患者在透析开始前因功能正常的通路而死亡。在所有58例BVT中,46.8±10.8%在3年时仍在发挥功能,中位生存期为30.8个月。将分析限于最终使用的46例BVT,3年的初级和次级通畅率分别为38.3±7.7%和56.5±12.6%。BVT失败的患者中存在较低的射血分数(p = 0.054)和更多的先前永久性透析导管(p = 0.005)。与AVF相比,BVT的3年初级和次级通畅率相似。在观察期内,BVT的次级通畅率明显优于AVG;在3年时,通畅率分别为56.5±12.6%和9.1±6.0%(p = 0.002)。贵要静脉动静脉内瘘是有价值的血液透析通路。尽管近20%新植入的BVT在首次使用前无法发挥功能,但那些功能正常的BVT中位生存期超过6年,38%在初次使用后3年内不需要干预。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验